CCT369260

Cat. No. M21157

All AbMole products are for research use only, cannot be used for human consumption.

For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.

CCT369260 is an orally active, B-cell lymphoma 6 (BCL6) inhibitor with antitumor activity and an IC50 value of 520 nM.

Molecular Weight	508.99
Formula	C24H31ClF2N6O2
CAS Number	2253878-44-1
Solubility (25°C)	DMSO ≥ 200 mg/mL
Storage	Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month

Related Bcl-2 Products
ABT-263 ABT-263 (Navitoclax) is a potent, orally bioavailable inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-x (L), and Bcl-w.
ABT-737 ABT-737 is a potent and selective inhibitor of B-cell lymphoma-2 (BCL-2) family proteins, in small cell lung cancer.
AT-101 AT-101 (R-(-)-gossypol acetic acid) is a pan small molecule inhibitor of Bcl-2, Bcl-xL, and Mcl-1.
ABT-199 ABT-199 (Venetoclax) is a highly potent, orally bioavailable and BCL-2 inhibitor. ABT-199 is the first inhibitor targeting Bcl-2 and PPI.
TW-37 TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM, respectively.

Catalog